Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • ROOMS:

Generic Drugs Stocks' Research Reports Released on Catalyst Pharma, Flexion Therapeutics, Supernus Pharma, and Allergan

NEW YORK, Jan. 9, 2018 /PRNewswire/ -- strives to bring the best free research to the investment community.  Today we are offering reports on CPRX, FLXN, SUPN, and AGN which can be accessed for free by signing up to On Monday, the NASDAQ Composite ended the day at 7,157.39, up 0.29%; the Dow Jones Industrial Average edged 0.05% lower, to finish at 25,283.00; and the S&P 500 closed at 2,747.71, marginally gaining 0.17%. US markets saw six out of nine sectors finishing the day in green, two in red, and one in neutral territory. has initiated research reports on the following Drugs - Generic stocks: Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), Flexion Therapeutics Inc. (NASDAQ: FLXN), Supernus Pharmaceuticals Inc. (NASDAQ: SUPN), and Allergan PLC (NYSE: AGN). All you have to do is sign up today for this free limited time offer by clicking the link below.

Catalyst Pharmaceuticals

Coral Gables, Florida-based Catalyst Pharmaceuticals Inc.'s stock finished Monday's session 1.90% lower at $3.88 with a total trading volume of 605,327 shares. The stock has gained 40.07% over the past three months and 234.48% in the previous twelve months. The Company's shares are trading above their 50-day and 200-day moving averages by 8.52% and 43.31%, respectively. Moreover, shares of Catalyst Pharma, which focuses on the development and commercialization of therapies for people with rare debilitating diseases, have a Relative Strength Index (RSI) of 49.22. Get the full research report on CPRX for free by clicking below at:

Flexion Therapeutics

Shares in Burlington, Massachusetts headquartered Flexion Therapeutics Inc. rose 1.27%, ending yesterday's session at $25.57 with a total trading volume of 647,232 shares. The stock has gained 30.39% over the past twelve months. The Company's shares are trading above their 50-day and 200-day moving averages by 5.52% and 10.45%, respectively. Moreover, shares of Flexion Therapeutics, which focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions, have an RSI of 53.24. Gain free access to the research report on FLXN at:

Supernus Pharmaceuticals

On Monday, Rockville, Maryland-based Supernus Pharmaceuticals Inc.'s stock saw a drop of 1.33%, to close the day at $40.95. A total volume of 647,097 shares was traded, which was higher than their three months average volume of 450.45 thousand shares. The Company's shares have advanced 12.35% in the last one month and 52.23% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 5.09% and 4.53%, respectively. Additionally, shares of Supernus Pharma, which focuses on the development and commercialization of products for the treatment of central nervous system diseases in the US, have an RSI of 58.49.

On December 28th, 2017, research firm B. Riley FBR, Inc. reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $50 a share to $54 a share. Register for your free report coverage on SUPN at:


Shares in Dublin, Ireland headquartered Allergan PLC ended the day 1.00% lower at $170.56. A total volume of 2.79 million shares was traded. The stock has gained 1.52% in the last one month. The Company's shares are trading below their 50-day moving average by 0.68%. Furthermore, shares of Allergan, which develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide, have an RSI of 52.48. Get the free research report on AGN at:

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:

SOURCE Wall St. Equities

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.